2023 Surgical Oncology Cancer Symposium

Memphis, TN US
September 30, 2023

The University of Tennessee Health Science Center Division of Surgical Oncology is hosting a one-day symposium on the management of colorectal cancer. The purpose of this activity is to provide healthcare providers with up-to-date strategies in the evaluation and management of patients with localized and metastatic colorectal cancer. The symposium will provide a unique opportunity for clinicians involved in the care of these patients to learn from and interact with leading national and local faculty to increase clinical knowledge, apply new data into practice, and ultimately improve patient outcomes.

Target Audience

  • Medical Oncologists
  • Radiation Oncologists
  • Surgeons (oncology, colorectal, general, hepatobiliary)
  • Gastroenterologists
  • Radiologists
  • Pathologists
  • Genetic Counselors
  • Physicians
  • Allied Health Professionals
  • Residents
  • Fellows
  • Nurses
  • Medical Students

Professional Practice Gap 

Colorectal cancer remains among the most commonly diagnosed cancers and is responsible for a high proportion of cancer-related deaths in the United States. Over the last decade, there have been significant updates in the treatment of these patients. With the advent of total neoadjuvant therapy for rectal cancer, it is essential for clinicians to recognize nuances that influence the sequencing of chemotherapy and chemoradiation for these patients. In addition, understanding the evaluation and surveillance for rectal cancer patients who may be candidates for a “watch and wait” approach is important. Also, it is important that clinicians appreciate the evolving role of ctDNA in surveillance and treatment of colorectal cancer patients. Moreover, it is essential to appreciate how microsatellite status and mutational profiling inform appropriate utilization of immunotherapy and targeted therapies in colorectal cancer. Finally, having an appreciation for the role of metastasectomy for patients with stage IV disease and how surgery can improve survival in appropriately selected patients is critical to optimizing outcomes. This symposium is designed to give providers of all levels a contemporary perspective on the multidisciplinary management of colorectal cancer patients.

Learning Objectives

  • Review evolving strategies in total neoadjuvant chemotherapy for rectal cancer, including updates in recent clinical trials.
  • Recognize when and how to perform screening for hereditary conditions in patients with colorectal cancer.
  • Appreciate the indications and outcomes for immunotherapy in patients with colorectal cancer.
  • Describe the application of circulating tumor DNA in the surveillance and treatment decisions in patients with colorectal cancer.
  • Review the utility of biologic therapies in colorectal cancer, understanding what agents to use and when to use them.
  • Discuss the role of surgical management for patients with metastatic colorectal cancer.
Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Course opens: 
Course expires: 
Event starts: 
09/30/2023 - 7:30am CDT
Event ends: 
09/30/2023 - 3:00pm CDT
*** This live activity has been approved for up to 6 AMA PRA Category 1 CreditsTM****
2023 Surgical Oncology Cancer Symposium: State of the Art Management Colorectal Cancer
  Saturday, September 30, 2023 
TimeslotPresentation #PresentationPresenter
7:30 AM - 8:00 AMN/AContinental Breakfast 
7:50 AM - 8:00 AMN/AIntroduction / Opening RemarksPaxton Dickson, MD
8:00 AM - 8:20 AM1PDF icon Current Concepts in Chemotherapy for Rectal CancerHanna Sanoff, MD, MPH
8:20 AM - 8:40 AM2PDF icon Radiation Therapy: When and For How Long?Sarah Hoffe, MD
8:40 AM -9:00 AM3PDF icon Watch and Wait - Where are We in 2023?David Shibata, MD
9:00 AM - 9:20 AM4PDF icon Germline Testing for Colorectal Cancer - When is it Necessary?Bryson Katona, MD, PhD
9:20 AM - 9:40 AM Question and Answer 
9:40 AM - 10:00 AMN/ABreak 
10:00 AM - 11:00 AM5PDF icon Case-Based Multidisciplinary Panel Discussion: Rectal CancerN/A
11:00 PM - 11:40 PMN/ALunch / Visit with Exhibitors 
11:40 AM - 12:00 PM6PDF icon Immunotherapy in Colorectal CancerAndrea Cercek, MD
12:00 PM - 12:20 PM7PDF icon Real World Application for ctDNA in Colorectal CancerVan Morris, MD
12:20 PM - 12:40 PM Question and Answer 
12:40 PM - 12:50 PMN/ABreak 
12:50 PM - 1:10 PM8PDF icon Biologic Therapies - What and When?Saurin Chokshi, MD
1:10 PM - 1:30 PM9PDF icon Contemporary Management of Liver MetastasesChing-Wei Tzeng, MD
1:30 PM - 1:50 PM10PDF icon CRS and HIPEC in Colorectal Cancer Indications and OutcomesIan Solsky, MD
1:50 PM - 2:10 PM Question and Answer 
2:10 PM - 2:20 PMN/ABreak 
2:20 PM - 3:20 PM11PDF icon Case-Based Multidisciplinary Panel Discussion: Management of Metastatic DiseaseN/A
3:20 PM - 3:30 PMN/AClosing Remarks and AdjournmentPaxton Dickson, MD
  Total CME6 hours

PDF icon 2023 Cancer Brochure


Memphis - Mooney Library
875 Monroe Avenue
Room 201
Memphis, TN 38163
United States

Parking Map

Parking is available in the H Parking Garage at 920 Madison Avenue at the Hamilton Eye Institute Building.
Medical director(s)

Paxton V Dickson

has no relevant financial relationships to disclose at this time.

AMA Credit Designation: The University of Tennessee College of Medicine (UTCOM) designates this live activity for a maximum of
6 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Education for Non-Physicians: The UTCOM will issue Certificates of Participation to non-physicians for participating in this activity and designates it for CEUs using the national standard that 1 hour of educational instruction is awarded .1 CEU.
Accreditation: The UTCOM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Please login or register to take this course.